Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Gilead Sciences Q1 2024 Adj EPS $(1.32) Beats $(1.49) Estimate, Sales $6.10B Miss $6.34B Estimate

Author: Benzinga Newsdesk | April 25, 2024 04:02pm
Gilead Sciences (NASDAQ:GILD) reported quarterly losses of $(1.32) per share which beat the analyst consensus estimate of $(1.49) by 11.41 percent. The company reported quarterly sales of $6.10 billion which missed the analyst consensus estimate of $6.34 billion by 3.79 percent. This is a 3.97 percent decrease over sales of $6.35 billion the same period last year.

Posted In: GILD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist